Brokers Offer Predictions for Tourmaline Bio FY2025 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Tourmaline Bio in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings of ($3.48) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($2.99) per share.

Several other analysts have also issued reports on the stock. BMO Capital Markets began coverage on shares of Tourmaline Bio in a research report on Friday, December 6th. They set an “outperform” rating and a $50.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $49.00 price objective on shares of Tourmaline Bio in a research note on Wednesday, December 11th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Tourmaline Bio in a report on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tourmaline Bio presently has a consensus rating of “Buy” and an average target price of $54.00.

Tourmaline Bio Stock Down 0.7 %

NASDAQ TRML opened at $17.51 on Wednesday. The company has a 50-day moving average price of $21.82 and a 200-day moving average price of $20.97. Tourmaline Bio has a 52 week low of $12.12 and a 52 week high of $48.31. The firm has a market capitalization of $448.96 million, a P/E ratio of -6.21 and a beta of 2.36.

Tourmaline Bio (NASDAQ:TRML) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.06.

Institutional Trading of Tourmaline Bio

A number of hedge funds and other institutional investors have recently modified their holdings of TRML. SG Americas Securities LLC boosted its holdings in Tourmaline Bio by 3.4% in the 4th quarter. SG Americas Securities LLC now owns 34,812 shares of the company’s stock worth $706,000 after buying an additional 1,140 shares during the period. Brooklyn Investment Group purchased a new position in shares of Tourmaline Bio in the fourth quarter valued at about $32,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Tourmaline Bio by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,932 shares of the company’s stock worth $127,000 after acquiring an additional 1,920 shares during the period. JPMorgan Chase & Co. grew its position in shares of Tourmaline Bio by 16.5% during the third quarter. JPMorgan Chase & Co. now owns 14,804 shares of the company’s stock worth $381,000 after purchasing an additional 2,100 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Tourmaline Bio by 3.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,571 shares of the company’s stock valued at $1,634,000 after purchasing an additional 2,147 shares during the period. 91.89% of the stock is owned by hedge funds and other institutional investors.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.